COMMUNIQUÉS West-GlobeNewswire

Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024
14/02/2024
TORONTO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 fourth quarter and full-year earnings conference call on Thursday, February 29, 2024 [...]
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
14/02/2024
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
14/02/2024
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal [...]
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
14/02/2024
SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after [...]
RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
14/02/2024
ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
14/02/2024
IRVINE, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
14/02/2024
MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
Prime Medicine Announces Proposed Public Offering of Common Stock
14/02/2024
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
14/02/2024
-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery -Poster Presentation at [...]
WW International, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
14/02/2024
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or “the Company”) will release its results for the fourth quarter and full year 2023 after market close on [...]
Pennant Announces Fourth Quarter and Year-End 2023 Earnings Release and Call
14/02/2024
EAGLE, Idaho, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it [...]
Olansky Dermatology & Aesthetics welcomes Dr. Ajdin Kobic to acclaimed roster
14/02/2024
Board-certified dermatologist, Mohs micrographic, and reconstructive surgeon now providing care at Olansky Dermatology & Aesthetics ATLANTA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics – [...]
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
14/02/2024
Media Release COPENHAGEN, Denmark; February 14, 2024 Genmab filed Form 20-F for the financial year 2023 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial [...]
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
14/02/2024
Regional Medical Oncology Center is activated and open to screen patients Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment which was previously anticipated Q3/24 is now [...]
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
14/02/2024
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
14/02/2024
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc [...]
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
14/02/2024
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: [...]
EssilorLuxottica Q4/FY 2023 Results - 2023: another record year for EssilorLuxottica
14/02/2024
Q4/FY 2023 RESULTS 2023: another record year for EssilorLuxottica Group revenue at constant exchange rates 1 +7.1% in Q4 and FY, third consecutive year >7% Nice acceleration in North America in Q4, EMEA keeping the [...]
EssilorLuxottica résultats T4 et annuels 2023 - 2023: nouvelle année record pour EssilorLuxottica
14/02/2024
Résultats T4 et annuels 2023 2023 : nouvelle année record pour EssilorLuxottica Hausse de +7,1 % du chiffre d'affaires du Groupe au T4 et sur l’année à taux de change constants 1 ; troisième année consécutive supérieure [...]

Pages